. 2017 Sep 18;102(11):4218–4225. doi: 10.1210/jc.2017-01210

Table 1.

Clinical Characteristics of Patients With Acromegaly Before and After Biochemical Control of Acromegaly and of Controls

Variable	Acromegaly Pretherapy (n = 20)	Acromegaly Posttherapy (n = 16)	Controls (n = 20)	P Value Acromegaly Pretherapy vs Controls	P Value Acromegaly Pretherapy vs Posttherapy	P Value Acromegaly Posttherapy vs Controls
Age, y	47 ± 16		47 ± 17	1.0
Male/female, n	11/9	9/7	11/9	1.0
Weight, kg	92.1 ± 22.8	92.7 ± 24.2	91.0 ± 23.1	0.9	0.3	0.8
BMI, kg/m²	30.4 ± 5.4	30.8 ± 6.5	30.5 ± 5.9	0.9	0.2	0.9
GH nadir, ng/mL^a	8.3 (4.3, 10.9)	0.2 (0.1, 0.45)	0.05 (0.05, 0.1)	<0.0001	0.0001	0.0001
IGF-1, ng/mL^a	787 (641, 1099)	249 (191, 317)	174 (110, 209)	<0.0001	<0.0001	0.002
IGF-1, standard deviation score	4.3 ± 0.9	1.3 ± 0.7	0.2 ± 0.8	<0.0001	<0.0001	0.0002
HOMA-IR^a	1.81 (1.55, 3.73)	0.98 (0.49, 1.53)	1.35 (0.57, 2.51)	0.08	0.01	0.3
Fasting glucose, mg/dL	92 ± 13	89 ± 14	90 ± 12	0.5	0.8	1.0
Glucose AUC, mg/dL × 120 min	17614 ± 5123	17468 ± 5193	14792 ± 2757	0.06	0.6	0.08
Fasting insulin, μU/mL^a	9 (7, 17)	5 (2, 8)	6 (3, 12)±5	0.045	0.003	0.5
Insulin AUC, μU/mL × 120 min^a	6828 (5152, 8196)	3098 (2094, 4272)	3827 (1854, 4580)	0.004	0.008	0.8

Data are presented as mean ± standard deviation for normally distributed data and as median (interquartile range) for nonnormally distributed data. P values in boldface are significant.

Abbreviation: AUC, area under the curve.

^{^a}

Nonnormally distributed data.